MedImmune, the global biologics research and development arm of AstraZeneca, and 4D Molecular Therapeutics (4DMT), a company focusing on Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, announced a collaboration to develop and commercialize a gene therapeutic for patients with chronic lung disease, utilizing 4DMT’s novel discovery platform to…